Abstract-Inflammation is an important innate immune response to infection or tissue damage. Inflammasomes are involved in the onset and development of inflammation. The NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome is the best-characterized inflammasome. Recent evidence has indicated the importance of the NLRP3 inflammasome in the pathophysiology of cardiovascular disorders. To further understand the roles of the NLRP3 inflammasome in the cardiovascular system, we provide a comprehensive overview and discuss the remaining questions. First, a summary of NLRP3 inflammasome in the cardiovascular system is introduced. Then, the associations between NLRP3 inflammasome and cardiovascular disorders are presented. Finally, we discuss existing problems and potential directions with this issue. This review highlights the current knowledge about the role of the NLRP3 inflammasome in the cardiovascular system.
I
nflammation underlies a wide variety of physiological and pathological processes. [1] [2] [3] In particular, chronic inflammation constitutes the biochemical basis for many diseases of modern humans. 4 Inflammasomes are multiprotein complexes that serve as molecular platforms to activate caspase-1 and other caspases, and regulate the maturation of potent proinflammatory cytokines, including IL (interleukin)-1β and IL-18. 5, 6 The ultimate result is the facilitation of an inflammasome-mediated immune response. 3, 7 To date, the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome has attracted more attention than others and is the best-characterized member of the NLR family of inflammasomes. 7, 8 Furthermore, NLRP3 is the main inflammasome sensor in the context of cardiovascular diseases. 9 After exogenous pathogen-associated molecular patterns or endogenous damage-associated molecular patterns are recognized, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] the activation of the NLRP3 inflammasome ultimately produces inflammatory responses in various disease, especially chronic inflammatory disorders. 22 The activation of the NLRP3 inflammasome has been demonstrated to participate in various pathological processes and disorders, including obesity, [23] [24] [25] diabetes mellitus, 26 gout, 26, 27 rheumatoid arthritis, 28 tumors, [29] [30] [31] [32] [33] [34] [35] [36] subarachnoid hemorrhage, 37, 38 neurodegenerative disorders, 13, [39] [40] [41] [42] Crohn disease, 43 chronic obstructive pulmonary disease, 44, 45 asthma, 44 the cryopyrin-associated periodic syndrome, 46 geographic atrophy, 17 and sepsis (Table 1) .
Furthermore, activation of the NLRP3 inflammasome can be tightly controlled by some molecules and pharmaceuticals, including melatonin (because of its inhibition of the NF-κB [nuclear factor κB] pathway and reactive oxygen species [ROS] production), 4, 37, [47] [48] [49] dopamine (because of its promotion of NLRP3 ubiquitination and degradation), 50 adiponectin (because of its inhibition of the NF-κB pathway), 51 and nucleoside reverse transcriptase inhibitors (because of its suppression of P2X7-mediated NLRP3 inflammasome activation). 16 The inflammatory reaction in the cardiovascular system has been demonstrated to be important for the incidence of cardiovascular disorders, and anti-inflammatory therapies may be beneficial. [52] [53] [54] [55] Notably, the NLRP3 inflammasome has been linked to the pathophysiology of cardiovascular diseases, 56, 57 including heart failure (HF) 58 and myocardial ischemia (MI). 59 Inhibition of the NLRP3 inflammasome has been demonstrated to contribute Previously, the NF-κB network has been implicated as a proinflammatory core in the development of numerous cardiovascular disorders. [73] [74] [75] [76] Importantly, in response to proinflammatory stimuli, NF-κB is firstly activated to promote the expression of pro-IL-1β and NLRP3 (NLRP3 inflammasome priming). 3, 4, 14, 51, 77 Several nontranscriptional priming signals also contribute to the NLRP3 inflammasome priming, such as JNK1 (c-Jun N-terminal kinase-1)-mediated NLRP3 S194 phosphorylation and mitochondrial ROSmediated deubiquitination. 78, 79 However, the signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation, and a second stimulus, such as extracellular ATP, mitochondria-generated ROS, 22 or crystalinduced damage, is required for the actual assembly of NLRP3 inflammasome (NLRP3 inflammasome activation). 77 
Expression of the NLRP3 in the Cardiovascular System
Inflammasome activation leads to caspase-1-dependent programmed cell death, which is referred to as pyroptosis. Pyroptosis of cardiomyocytes has been observed after myocardial infarction. 64 Furthermore, the expression of NLRP3 in normal vascular tissues and the normal heart has been reported in several studies. 72, [80] [81] [82] Cytoplasmic expression of NLRP3 has been detected in cardiac muscle cells of BALB/c mice 82 and Chinese yellow chickens. 81 In another study, NLRP3 was reported to be expressed in cardiac microvascular endothelial cells after myocardial ischemia/reperfusion (I/R) injury. 80 As an important site of inflammation, microvascular endothelial cells are both active participants in and regulators of inflammatory processes. 73, 83 As a major nonmuscle cell compartment of the heart, cardiac microvascular endothelial cells play a key role in triggering cardiomyocyte injury. 84 Apoptosis of cardiac endothelial cells precedes the apoptosis of cardiomyocytes, indicating that the NLRP3 inflammasome may bridge the interactions between endothelial cells and cardiomyocytes. 84 In general, the NLRP3 inflammasome is expressed at low levels in heart tissues. 81, 82 Liu et al 80 detected the expression of the NLRP3 inflammasome in neonatal cardiomyocytes from C57BL/6J mice. Two other studies have detected its expression in adult heart tissues. 81, 82 Among the various tissues examined, the heart expresses fewer NLRP3 proteins than tissues involved in immune defense, and the assembly of functional inflammasomes requires the upregulation of at least 2 components. 72 Multiple components are required because the activation of the NLRP3 inflammasome occurs in 2 distinct steps. Under normal conditions, that is, in the absence of triggers, NLRP3 expression, and NLRP3 inflammasome activity in the heart may be limited.
Inflammasome activation has been observed in cardiac fibroblasts during myocardial I/R injury. 85, 86 During the inflammatory response associated with cardiac repair, NLRP3 has been shown to be activated in cardiac fibroblasts in response to TGF-β (transforming growth factor β) stimulation, which is involved in the release of cytokines and chemokines. 87, 88 Interestingly, NLRP3-mediated regulation of myofibroblast differentiation occurred independently of the inflammasome, 88 Instead, mitochondrially localized NLRP3 potentiated the effects of ROS to augment the receptorregulated Smad activation and ultimately led to ECM (extracellular matrix) and myocardial remodeling. 88 Inflammasome-and cytokine-independent roles for NLRP3 in regulating host defense mechanisms have been observed in doxorubicininduced cardiotoxicity, kidney injury, and infectious illness. [89] [90] [91] [92] In addition to its expression in cardiovascular tissues, NLRP3 inflammasome expression in immune cells also contributes to cardiovascular disorders. The endogenous Clinical study in patients and in vivo study with mice Heneka et al 13, 39 Crohn disease Mutations in NLRP3 are associated with the susceptibility to Crohn disease. Clinical study in patients Villani et al 43 COPD and asthma The NLRP3 inflammasome is associated with chronic inflammation in airways, and its activation contributes to the development of COPD and asthma.
Clinical study in patients and in vivo study with mice
Birrell et al 44 and Singh et al 45 
CAPS
The NLRP3 inflammasome plays an important role in the development of CAPS. Clinical study in patients and in vivo study with mice Lee et al 46 Geographic atrophy Elevated NLRP3 levels contribute to the molecular pathogenesis of geographic atrophy.
Clinical study in patients and in vivo study with mice Tarallo et al 17 CAPS indicates cryopyrin-associated periodic syndromes; COPD, chronic obstructive pulmonary disease; NLRP3, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3. Figure 1 . The activation of the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome. The NLRP3 inflammasome can be activated by various exogenous pathogen-associated molecular patterns (PAMPs) or endogenous damage-associated molecular patterns (DAMPs). First, the priming of NLRP3 inflammasome is mostly mediated by NF-κB (nuclear factor κB) activation. Then, a second signal promotes the components produced during priming to form the functional NLRP3 inflammasome. Finally, caspase-1, IL (interleukin)-1β, and IL-18 are produced on the platform of NLRP3 inflammasome. ASC indicates adaptor protein apoptosis-associated speck-like protein containing a caspase-recruitment domain; and TLR, Toll-like receptor. December 2018 lipid metabolite sphingosine is a damage-associated molecular pattern that triggers and activates the NLRP3 inflammasome-dependent secretion of IL-1β from macrophages. 93 Furthermore, in an important model of acute vasculitis and an acquired cardiac disease, Kawasaki disease, an extract of Lactobacillus casei cell walls induced IL-1β maturation, and secretion in macrophages, which was dependent on the NLRP3 inflammasome. 94 In particular, genetic variants have been detected in patients with coronary artery disease (CAD), which is associated with increased NLRP3 mRNA levels in peripheral blood mononuclear cells (PBMCs). 95 However, NLRP3 inflammasome levels are decreased in PBMCs after treatment with statins. 70 The increased NLRP3 inflammasome activation and IL-1β secretion by monocytes from the PBMCs of patients with the acute coronary syndrome are suppressed by colchicine. 96 Although the THP-1 cell line is not the preferred model to study the inflammasome, 97 it is always used to study atherosclerosis, and in vitro studies showed that the NLRP3 inflammasome can be activated to secrete IL-1β in THP-1 cells. 11, 70, 98, 99 Levels of the NLRP3 inflammasome are decreased in THP-1 cells treated with statins and saikosaponins A. 70, 98 Recent studies have shown that the NLRP3 inflammasome is expressed in dendritic cells and CD4 + T cells, [100] [101] [102] [103] [104] which should be further studied in the context of cardiovascular disorders. The expression of both NLRP3 protein and the NLRP3 inflammasome has been observed in various cells of the cardiovascular system (Table 2 ). NLRP3 inflammasome activation in various cell types contributes to cardiovascular disorders. NLRP3 may have both inflammasome-dependent and -independent roles in the cardiovascular system.
NLRP3 Inflammasome in Atherosclerosis
Chronic and sterile inflammation driven by the innate immune system plays important roles in the development and progression of atherosclerosis. [105] [106] [107] However, the details of the inflammatory pathways in atherosclerosis are unclear. 107 Inflammasomes, especially the NLRP3 inflammasome, are key players in sterile inflammation, 57, 62 and the focus of this section is the role of NLRP3-mediated inflammation in atherosclerosis.
Ex vivo human studies showed that the mRNA and protein levels of the NLRP3 inflammasome (measured by flow cytometric assessment and real-time polymerase chain reaction) in PBMCs were higher in patients with CAD, especially those with the acute coronary syndrome, 108 than in the non-CAD patients. 70 Furthermore, measured by quantitative realtime polymerase chain reaction and immunohistochemistry, the mRNA and protein levels of the NLRP3 inflammasome (NLRP3, IL-1β, and IL-18) in the arterial and subcutaneous adipose tissues were positively associated with atherosclerotic risk factors, including hypertension, diabetes mellitus, obesity, smoking, total cholesterol, and dyslipidemia, as well as hyperuricemia, 109, 110 but negatively associated with HDL (high-density lipoprotein) cholesterol. 109 Additionally, the NLRP3 expression in PBMCs and the arterial tissues is separately positively correlated with the severity of coronary atherosclerosis and CAD. 108, 109 Afrasyab et al 108 conducted Multivariate Cox regression analysis, Kaplan-Meier analysis, and receiver operating characteristic curves. The results of these analyses indicated that NLRP3 is an independent predictor of major adverse cardiac events, and NLRP3 showed good predictive value for major adverse cardiac events. The clinical evidence pertaining to the NLRP3 inflammasome in atherosclerosis has been summarized in Table 3 .
The elevated NLRP3 inflammasome has also been observed in animal studies, and in vivo studies further explored the potential activation mechanisms of the NLRP3 inflammasome in atherosclerosis. Janoudi et al 111 recently summarized that by activating the NLRP3 inflammasome, cholesterol crystals initiate inflammation leading to IL-1β production that induces CRP (C-reactive protein), which finally results in the destabilization of the atherosclerotic plaque. Especially, Duewell et al 60 showed that cholesterol crystals induced early atherosclerosis and inflammasome-dependent IL-18 levels are decreased in mice deficient in components of the NLRP3 inflammasome, which provide further definitive evidence to support that NLRP3 inflammasome is required for atherogenesis and activated by cholesterol crystals. As an important integral membrane protein archetypal pattern recognition receptor, CD36 could recognize and bind with multiple pathogen-associated molecular patterns and damage-associated molecular patterns, such as oxidized LDL (low-density lipoprotein). 112 Sheedy et al 113 demonstrated the importance of CD36 in cholesterol crystals-induced NLRP3 inflammasome activation. Furthermore, monosodium urate crystals have also been observed to increase the gout-associated coronary heart disease risk through the activation of the NLRP3 inflammasome. 114 The roles of the NLRP3 inflammasome in atherosclerosis were further supported by in vitro studies. Monocyte-derived microparticles are emerging as critical transducers of inflammatory signals and have been suggested to link cardiovascular risk factors to vascular injury. 99, 115 During lipopolysaccharide-evoked release of monocyte-derived microparticles, the NLRP3 inflammasome and its key components were significantly upregulated, and endothelial cells were activated. 51 Moreover, knockdown of NLRP3 in THP-1 monocytic cells reduced the activity of the microparticles and decreased the microparticle-dependent induction of cell adhesion molecules by blocking the IL-1R on endothelial cells. 51 Most of this mechanistic evidence for this hypothesis still needs to be clinically demonstrated.
The regulation of NLRP3 inflammasome has been explored in clinical studies. Atorvastatin downregulates the expression of the NLRP3 inflammasome in PBMCs in CAD, indicating that the suppression of the NLRP3 inflammasome may contribute to the inhibitory effects of atorvastatin on chronic inflammation and atherogenic progression. 70 Another study reported that the activation of the NLRP3 inflammasome, indicated by serum IL-1β, IL-18 via ELISA, in acute coronary syndrome patients was also suppressed by colchicine. 65 The IKBKE (inhibitor of κB kinase epsilon) is important in the host defense against viral infection 116 and was recently demonstrated to be a novel regulator that limits the chronic inflammation associated with atherosclerosis by inhibiting the priming of the NLRP3 inflammasomes in macrophages. The pathogenic relevance of IKBKE was indicated by its localization in the macrophages found in atherosclerotic plaques. 117 Genetic ablation of IKBKE resulted in enhanced and prolonged priming of the NLRP3 inflammasome in cultured macrophages that could be reversed by restoring IKBKE. Whereas this mechanistic evidence still needs to be confirmed in clinical studies. Collectively, these results indicate that the NLRP3 inflammasome is upregulated during atherosclerosis and that the expression levels of NLRP3 are positively associated with the atherosclerotic risk factors and major adverse cardiac events (Figure 2 ). The NLRP3 inflammasome can be activated by danger signals, and this process can be inhibited by pharmacological or molecular interventions (Figure 2) . Notably, the effects of a therapeutic human monoclonal antibody against IL-1β, canakinumab, in atherosclerotic disease have been tested in the CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcomes Study). 118 The CANTOS group found that 150 mg canakinumab every 3 months could significantly lower the recurrent rate of cardiovascular events. 119 Further analysis showed that the levels of high-sensitivity CRP may be used to identify the population that is sensitive to canakinumab. 120 Although no significant difference was observed in all-cause mortality (canakinumab versus placebo, 0.94; 95% CI, 0.83-1.06; P=0.31), canakinumab utilization may be associated with a higher incidence of fatal infection. Thus, canakinumab and IL-1β inhibition may be beneficial for patients with atherosclerosis.
NLRP3 Inflammasome in MI disorders
Inflammation has been widely reported to be involved in the pathophysiology of MI, and recent studies have indicated the inflammasome is a potential novel therapeutic target for preventing MI. 64, [121] [122] [123] Notably, interference with NLRP3 inflammasome signaling has been proposed to protect against MI. 59, 124 Myocardial NLRP3, IL-1β, and IL-18 are upregulated following MI. 64 In addition to a significant reduction in the infarct size at the site of acute MI, inhibition of NLRP3 inflammasome also preserved the cardiac function post-MI, in the presence or absence of reperfusion. 80, 124, 125 Previous studies have demonstrated that IL-1β interacts with the IL-1R on bone marrow myeloid progenitors to stimulate the production of monocytes and neutrophils, 126 and the NLRP3 inflammasome promoted neutrophilic influx. 62 The regulation of the NLRP3 inflammasome by several pharmaceutical agents contributes to the improvements following MI. By inhibiting NLRP3 activation, a specific cathepsin B inhibitor, CA-074Me, significantly attenuated the cardiac dysfunction and reduced the cardiomyocyte size and cardiac fibrosis in an experimental model of MI. 127 Similarly, MI injury also can be improved by sodium tanshinone IIA sulfonate, 128 and diltiazem hydrochloride, 128 by inhibiting cardiac NLRP3 inflammasome activation.
Some studies have focused on clarifying the possible mechanisms of NLRP3 inflammasome regulation during MI. TXNIP (thioredoxin-interacting protein), a member of the arrestin protein superfamily, is a regulator of metabolism and an inhibitor of the antioxidant thioredoxin. 129 Deletion of TXNIP in mice protects the myocardium from ischemic injury, 130 which suggests that this molecule may be involved in the regulation of the NLRP3 inflammasome in the heart. TXNIP is an important molecule to activate the NLRP3 inflammasome through direct interaction with NLRP3, 12 which may be driven by oxidative stress and ROS production. 131 TXNIP may act as a sensor of increasing levels of ROS, which cause it to dissociate from thioredoxin, and this promotes NLRP3 activation. 8, 12 Recent studies have shown that TXNIP activates the NLRP3 inflammasomes in the pathophysiology of MI. Ischemic heart tissue showed an enhanced interaction between TXNIP and NLRP3 in the cardiac microvascular endothelial cells. 80 Hu et al 128 found that ROS overproduction and increased TXNIP expression drives cardiac NLRP3 inflammasome activation, as well as IL-1β and IL-18 production. This impaired the STAT3 (signal transducer and activator of transcription 3) and insulin signaling pathways and finally led to disordered lipid metabolism in dogs with MI through PPAR-α (peroxisome proliferator-activated receptor α) overexpression. Mitochondrial homeostasis is essential for the maintenance of redox balance in cardiomyocytes. The generation of mitochondrial ROS contributes to myocardial ischemic injury, 132 whereas the NLRP3 inflammasome senses mitochondrial dysfunction, 22, 133, 134 indicating the possible activation mechanism of the NLRP3 inflammasome during MI. Targeting the activation of the NLRP3 inflammasome, especially the TXNIP-dependent NLRP3 inflammasome activation, may represent a novel therapeutic strategy to prevent HF and remodeling after MI (Figure 3) .
Myocardial I/R injury is a serious injury following the recovery of blood supply after MI. In addition to MI, NLRP3 inflammasome activation also contributed to the myocardial I/R injury and enlarged the infarct development. 85, 135 During myocardial I/R injury, the infiltration of macrophages and neutrophils could be inhibited by NLRP3 siRNA, which finally attenuated myocardial I/R injury. 80 Furthermore, myocardial I/R injury can be improved by 16673-34-0 through NLRP3 inflammasome inhibition. 136 Interestingly, although most studies have implied a negative role of the NLRP3 inflammasome in myocardial I/R injury, this conclusion has been questioned. The absence of NLRP3 results in an increased size of the myocardial infarct after in vivo I/R, seemingly because of inhibition of Akt phosphorylation. 137 The mechanisms by which the RISK cardioprotective pathway are activated by the NLRP3 inflammasome/IL-1β still need to be investigated. Multiple cells that express the NLRP3 inflammasome participate in the pathophysiology of myocardial ischemic disorders, and therefore, it is necessary to use conditional NLRP3 knockout mice to confirm which NLRP3 inflammasome is important.
NLRP3 Inflammasome in Hypertension
Systemic hypertension and pulmonary hypertension are associated with marked dysregulation of the circulating inflammatory cytokines. [138] [139] [140] Notably, recent studies have suggested that the NLRP3 inflammasome plays important roles in the pathogenesis of hypertension. Accompanying the increased mean arterial pressure, heart rate, and plasma norepinephrine, rats fed a high-salt diet had higher levels of NLRP3 and IL-1β in the hypothalamic paraventricular nucleus than the normal-diet rats. 141 Bilateral hypothalamic paraventricular nucleus injection of gevokizumab (an IL-1β inhibitor) decreased the mean arterial pressure, heart rate, and plasma norepinephrine attenuated the levels of oxidative stress and restored the balance of the cytokines, 141 which implies that it may be feasible to target the IL-1β signaling. During monocrotaline-induced pulmonary artery hypertension in rats, the NLRP3 inflammasome has been demonstrated to be activated, and this activation could be ameliorated by ellagic acid. 142 Furthermore, by inhibiting NLRP3-induced inflammation and fibrosis, pirfenidone (an approved drug by FDA for treatment of idiopathic pulmonary fibrosis) protects against hypertension-induced myocardial fibrosis and ventricular remodeling. 143 As an important component of the NLRP3 inflammasome, ASC is also involved in the hypoxia-induced pulmonary hypertension and right ventricular remodeling and the increased protein levels of caspase-1, IL-18, and IL-1β. 144 Interestingly, these responses are attenuated in ASC −/− mice but not NLRP3 −/− mice, which may be because of that ASC is not unique to NLRP3.
NLRP3 Inflammasome in Infectious Cardiac Disease
The pathogenesis of the cardiac diseases induced by infections depends on immune-mediated mechanisms, but the specific processes involved in these relations are still not well understood. It is well known that innate immunity is activated in response to infection, and the activation of the NLRP3 inflammasome plays a critical role in the host protection against various pathogens. 90, [145] [146] [147] However, the NLRP3 inflammasome is also crucial for the development of septic myocardial injury, viral myocarditis, and cardiac parasitism.
Septic Myocardial Injury
Sepsis-induced myocardial injury is associated with high mortality and morbidity throughout the world. 148, 149 NLRP3 inflammasome activation is the basis of the cardiac electrical and functional defects in septic mice. 150 Another study showed that the activation of the NLRP3 inflammasome in cardiac fibroblasts is pivotal in septic myocardial injury. 151 Studies from us and others showed that blocking the NLRP3 inflammasome with melatonin and cortistatin contributes to the protection against the septic response in the hearts of septic mice. 47, 152 Furthermore, suppression of the NLRP3 inflammasome has been attributed to inhibition of the NF-κB pathway. We found that melatonin decreased the NF-κB-dependent proinflammatory response through sirtuin 1-dependent NF-κB deacetylation and restored the redox balance and mitochondrial homeostasis with the ultimate result of inhibiting the NLRP3 inflammasome. 47 
Viral Myocarditis
Coxsackievirus B3 infection induced NLRP3-dependent inflammasome activation both in vitro and in vivo. 20 After treatment with the caspase-1 inhibitor Ac-YVAD-CHO, the The potential activation mechanism of the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome in myocardial ischemia (MI). During MI, reactive oxygen species (ROS) production promotes TXNIP (thioredoxin-interacting protein) to dissociate from thioredoxin, and TXNIP further promotes NLRP3 activation. The activation of the NLRP3 inflammasome augments the infarct size, recruits inflammatory cells, and impairs cardiac function. Inhibiting the activation of the NLRP3 inflammasome may represent a novel therapeutic strategy to prevent heart failure and remodeling after MI. ASC indicates adaptor protein apoptosis-associated speck-like protein containing a caspase-recruitment domain; DI, diltiazem hydrochloride; IL, interleukin; and STS, sodium tanshinone IIA sulfonate.
severity of coxsackievirus B3-induced myocarditis was significantly alleviated, and the cardiac function was improved as indicated by the enhanced left ventricular ejection fraction and left ventricular fractional shortening. 20 In addition to its role in cardiomyocytes, the NLRP3 inflammasome plays important roles in immunocytes, such as macrophages, dendritic cells, and CD4 + T cells. [100] [101] [102] [103] These cells mediate host defense against virus via activation of the NLRP3 inflammasome. In viral myocarditis, the roles of the NLRP3 inflammasome in these cells need to be confirmed. In brief, blocking NLRP3 inflammasome activation may be beneficial to improve viral myocarditis, however, the targeted cells need further confirmation.
Cardiac Parasitism
T cruzi is an intracellular protozoan parasite that is the etiological agent of Chagas disease, a chronic infection that affects millions of people worldwide. 90 NLRP3 signaling was found to be one of the top pathways that are upregulated during a T cruzi infection. 21, 90 Furthermore, NLRP3
−/− , ASC −/− , and caspase-1 −/− infected mice exhibit a higher number of T cruzi parasites, and incidence of cardiac parasitism and heart inflammation, indicating the involvement of NLRP3 inflammasome in the control of the acute phase of T cruzi infection. 21, 90 Interestingly, neutralization of IL-1β and IL-18 and IL-1R genetic deficiency demonstrate that these cytokines have a minor effect on the capacity of macrophages to control T cruzi infection, indicating the protective effects of NLRP3 inflammasome are independent from cytokine production. 90 Thus, blocking NLRP3 inflammasome activation may be a promising therapeutic strategy for infectious cardiac diseases.
NLRP3 Inflammasome in Cardiomyopathy
Cardiomyopathy is the measurable deterioration in the ability of the myocardium to contract. Inflammatory processes underlie a broad spectrum of conditions that injure the heart muscle and cause both structural and functional deficits. 153 In this section, we focus on the role of the NLRP3 inflammasome in diabetic cardiomyopathy (DCM) and idiopathic DCM. In idiopathic DCM patients, the circulating levels of NLRP3, ASC, caspase-1, and IL-1β have been demonstrated to be higher. 154 Additionally, a high level of NLRP3 in the PBMCs is associated with decreased cardiac function and increased rehospitalization in idiopathic DCM patients. NLRP3 inflammasome activation also contributes to the development of DCM. 155 The NLRP3 inflammasome mediates the ROS-induced caspase-1 and IL-1β activation through the NF-κB and TXNIP pathway. NLRP3 inhibition may exert a protective effect on DCM 155 as indicated by the effects of rosuvastatin administration.
156

NLRP3 Inflammasome in HF
HF is a chronic disorder with a poor prognosis that causes a decreased quality of life and considerable healthcare costs. 157 MI triggers an intense inflammatory response that is essential for cardiac repair but which is also implicated in the pathogenesis of postinfarction remodeling and HF. 171, 172 Through the phospholipase C-inositol trisphosphate pathway, α-smooth muscle actin, matrix metalloproteinase-2 and 9, and collagen secretion were upregulated, finally leading to collagen and ECM secretion. 171 Activation of the NLRP3 inflammasome in calcineurin transgenic mice promotes myocardial inflammation and systolic dysfunction through the production of the proinflammatory cytokine IL-1β. 173 Via the IL-1β-IL-1RI pathway in the cardiac fibroblasts, tissue inhibitor metalloproteinase-2 was downregulated and the cardiac fibroblast phenotypic transversion was accelerated. 171 Furthermore, the activation of the NLRP3 inflammasome contributes to hypertension-induced myocardial fibrosis and ventricular remodeling, 144 which can be inhibited by pirfenidone. 143 A preclinical study showed that an NLRP3 inhibitor, 16673-34-0, also significantly suppressed the increased myocardial interstitial fibrosis and declining systolic function caused by doxorubicin in mice. 125 Targeting the early inflammatory response, especially the NLRP3 inflammasome, during various cardiovascular disorders provides an interesting target to attenuate ventricular remodeling and prevent HF.
How to Target NLRP3 Inflammasome
In patients with coronary atherosclerosis, NLRP3, IL-1β, and IL-18 in the subcutaneous adipose tissue are negatively correlated with the severity of atherosclerosis. 110 Furthermore, multivariate analysis demonstrated that the body mass index and the serum level of uric acid (which are associated with cardiovascular disorders, especially, atherosclerosis [174] [175] [176] [177] ) were predictors of the NLRP3 expression in the subcutaneous adipose tissue. 110 In chronic spinal cord injury, the formation and activation of the NLRP3 inflammasome can be observed in the visceral adipose tissue, where it further promotes the activation of the signaling mechanisms involved in cardiovascular disease. 178 This observation demonstrated that the NLRP3 inflammasome in the subcutaneous and visceral adipose tissue may play important roles in atherogenesis. Screening of specific populations by monitoring the NLRP3 inflammasome in the adipose tissue may be useful in targeting medical interventions to prevent the incidence of coronary atherosclerosis.
Furthermore, the NLRP3 expression has been demonstrated to be affected by lifestyle-associated diseases, and changes in a patient's lifestyle may contribute to the control of coronary atherosclerosis. 109, 110 Additionally, the NLRP3 expression in the subcutaneous adipose tissue is negatively correlated with the serum adiponectin levels. 110 The epicardial adipose tissue volume imbalance is strongly linked to human coronary atherosclerosis. 179 Furthermore, the epicardial adipose tissue volume index was positively correlated with the NLRP3 expression and negatively correlated with the adiponectin expression in the epicardial adipose tissue. 179 Adiponectin administration markedly attenuated the lipopolysaccharide-induced microparticle expression of the NLRP3 inflammasome. 51 Could adiponectin supplementation contribute to the inhibition of NLRP3 as a means to aid in therapeutic and rehabilitation countermeasures? The NLRP3 inflammasome is not specifically expressed only in heart tissue. 72 The NLRP3 mutation is associated not only with the pathological changes of heart but also amyloidosis of other tissues, such as the kidney. 180 Thus, the medical interventions must be performed systemically.
Pharmacological interventions targeting the NLRP3 inflammasome have been investigated in the context of cardiovascular protection. Recently, some novel pharmacological inhibitors of the NLRP3 inflammasome, MCC950 and 16673-34-0, have been developed. 136, 181, 182 The previous study showed that 16673-34-0 inhibited the activation of NLRP3 inflammasome and decreased caspase-1 production after I/R in mice. 182 Interestingly, in addition to the protection against myocardial I/R, 16673-34-0 exerted protective effects against acute peritonitis without affecting glucose metabolism. MCC950 and 16673-34-0 are still tested at preclinical stage and need further confirmation in clinical studies. Nonspecific pharmacological interventions also regulate the activation of NLRP3 inflammasome. The NLRP3 inflammasome levels can be markedly diminished by atorvastatin but not rosuvastatin in CAD. 70 Interestingly, rosuvastatin can protect against DCM by inhibiting the NLRP3 inflammasome. 156 As an important antioxidative and anti-inflammatory agent, [183] [184] [185] [186] [187] our study showed melatonin could inhibit NLRP3 inflammasome activation during septic myocardial injury. 47 Future translational studies are needed to determine whether specific or nonspecific pharmacological inhibitors are effective and whether NLRP3 inflammasome inhibition is a promising target for cardiovascular disorders.
Nonpharmacotherapy has also been suggested to be protective through inhibition of the NLRP3 inflammasome. Ethanol dose-dependently blocked the NLRP3 inflammasome activation and decreased the production of mature IL-1β. 188 However, ethanol had no significant effect on the expression of the NLRP3 or IL-1β mRNA in lipopolysaccharide-primed macrophages, which indicates that ethanol inhibits inflammasome activation rather than the synthesis of pro-IL-1β, and the protective effect of moderate alcohol consumption on coronary heart disease may be mediated by inhibition of the NLRP3 inflammasome activation. The NLRP3 inflammasome activity can be regulated by several novel interventions, including specific pharmacotherapy, nonspecific pharmacotherapy, and nonpharmacotherapy, all of which may be beneficial for the control of cardiovascular disorders.
Conclusions and Perspectives
The NLRP3 protein and the NLRP3 inflammasome are important in the cardiovascular system, including in cardiomyocytes. In most conditions, the activation of the NLRP3 inflammasome contributes to cardiovascular disorders, including atherosclerosis, MI, hypertension, infectious cardiac disease, cardiomyopathy, and HF (Figure 4) . However, some studies have reported that the absence of NLRP3 contributes to the incidence and deterioration of several cardiovascular disorders, 71 ,81,137,180,189 which indicates a dual role of the NLRP3 inflammasome in cardiovascular disorders. These data support the existence of endogenous negative regulators of the NLRP3 inflammasome to modulate its activity. 190 A priming process is necessary for the activation of the NLRP3 inflammasome during cardiovascular disorders, but the exact mechanisms are still unclear. It has been demonstrated that the activation of the NLRP3 inflammasome in various cells contributes to cardiovascular disorders. However, whether there is a division of labor among the multiple cell types, and the nature of the collaborations responsible for the activation of the NLRP3 inflammasome in the cardiovascular system are still unclear. The mechanisms by which NLRP3 contributes to cardiovascular disorders are also still unclear and may be both inflammasome dependent and independent.
In addition to the experimental evidence, population studies have also supported the participation of NLRP3 inflammasome in cardiovascular disorders. A pilot study demonstrated that the right ventricles of young urbanites from Southwest Mexico City had significant upregulation of NLRP3 and that levels of the NLRP3 inflammasome were influenced by the location of residence. This may explain the differences in the incidence of cardiovascular disorders but needs further verification. 191 Genetic studies have indicated a possible role for the NLRP3 inflammasome in cardiac diseases. The high-signal single nucleotide polymorphism rs1539019 on the NLRP3 gene may underlie cardiovascular disease. 192 In a meta-analysis of genome-wide association studies, NLRP3 was recently identified to be associated with the CRP levels conducted in a set of European samples. 193 The GRAIL (Gene Relationships Across Implicated Loci) results identified a single nucleotide polymorphism, rs10157379, located within or near the NLRP3 gene as being significantly associated with this gene's function. This result suggests that among all of the genes in the vicinity of the 24 lead single nucleotide polymorphisms, these genes should be prioritized as the most plausible functional candidate genes within the associated loci. 194 Furthermore, ASC particles are found in the serum of patients with active cryopyrin-associated periodic syndrome, implying NLRP3 inflammasome may act as an extracellular oligomeric complex to amplify the inflammatory response. [195] [196] [197] [198] [199] [200] [201] [202] However, whether circulating NLRP3 inflammasome can be used as novel biomarkers for cardiovascular disorders in the clinic still needs further confirmation.
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